摘要
目的观察缓释抗结核微球填充于骨支架后的骨密度测试情况，为减少术后抗结核治疗的副作用提供实验依据。方法采用骨密度仪分别观察人工同种异体骨（A组）、利福平（RFP）缓释微球-人工同种异体骨缓释复合体（B组）和RFP-人工同种异体骨复合体（c组）灌注前后骨密度的变化。结果灌注前A、B、C三组骨密度差异无统计学意义[A组：（0．191±0．018）g／cm2；B组：（0．186±0．016）g／cm2；C组：（0．1894-0．018）g／cm2；P〉0．05]，而灌注后A、B、C三组骨密度差异亦无统计学意义[A组：（0．1914-0．018）g／em。；B组：（0．1794-0．023）g／cm2；C组：（0．185．4-0．021）g／cm2；P〉0．05]。结论RFP微球使用超声波振荡方法可以与多孔隙的骨制备成抗结核缓释复合体，且灌注后不会对骨密度产生明显的干扰作用。
Objective To investigate bone mineral density （BMD） after filling in the bone scaffolds with anti-tuberculosis controlled-release microspheres, and provide experimental basis for decrease of the side effects of anti-tuberculosis therapy after spinal surgery. Methods The bone densitometer was used to observe the changes of bone mineral density before and after the infusion with the artificial allograft bone （ Group A）, the controlled release complex of the RFP Controlled-release microspheres-artificial allograft bone （ Group B）, and RFP-artificial allograft bone complex （ Group C）, respectively. Results BMDs of three groups before perfusion were not different significantly [Group A：（0. 191 ＋0. 018）g/cm2 ; Group B：（0. 186 ±0. 016）g/cm2; Group C： （0. 189±0. 018）g/ cm2; P 〉 0. 05 ]. BMDs of three groups after perfusion were not different significantly [ Group A：（0. 191 ± 0. 018）g/cm2 ; Group B： （0. 179 ±0. 023）g/cm2; Group C：（0. 185 ±0. 021）g/era2; P 〉0. 05]. Conclusions RFP mierospheres using ultrasonic vibration method and the porous bone were prepared to controlled-release anti-tuberculosis complex. BMD of three groups after perfusion were not influenced obviously.
出处
《中国医师杂志》
CAS
2014年第2期218-220,共3页
Journal of Chinese Physician
关键词
抗结核药
迟效制剂
微球体
骨密度
Antitubercular agents
Delayed-action preparations
Mierospheres
Bone density
